Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors inside the central anxious method, conolidine modulates alternate molecular targets. A Science Developments study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://seymourh531dff1.newsbloger.com/profile